Budesonide/Glycopyrronium/Formoterol: A Review in COPD
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
(BREZTRI AEROSPHERE™; TRIXEO AEROSPHERE™) is an inhaled fixed-dose
combination of the inhaled corticosteroid (ICS) budesonide, the long-acting
muscarinic antagonist (LAMA) glycopyrronium bromide and the long-acting β2-agonist
(LABA) formoterol fumarate approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is delivered via a pressurized metered-dose
Aerosphere inhaler and is formulated using co-suspension delivery technology.
In two pivotal phase III
trials of 24–52 weeks’ duration, budesonide/glycopyrronium/formoterol reduced the rates
of moderate/severe COPD exacerbations and improved lung function to a greater
extent than budesonide/formoterol and/or glycopyrronium/formoterol. Budesonide/glycopyrronium/formoterol
also demonstrated beneficial effects on dyspnoea, rescue
medication requirements and health-related quality of life (HR-QOL), and reduced the risk of all-cause mortality. Budesonide/glycopyrronium/formoterol
was generally well tolerated, with the tolerability profile being generally similar to that of the individual
components. Budesonide/glycopyrronium/formoterol provides a
useful and convenient option for the maintenance treatment of COPD, including for
those whose disease is inadequately controlled with dual ICS/LABA or LAMA/LABA
© Springer Nature Switzerland AG 2021